P postscript to my earlier response, some clever little *&%$ has...

First 154 Last

Share
Profile

Follow
clewless

158 Posts.

19

09/01/18

08:47

Post #: 30146525
Share

P

Originally posted by 48&34 ↑

I really admire and share your enthusiasm for the potential success of the. canntab X-R range in Australia. However my professional experience tells me that we have significant obstacles to overcome.
Starting with the CBD tablet becoming over the counter. Highly unlikely in the next few years.
The forms containing THC likely to be schedule 8, which will slow down prescriptions a lot.
Replacing all current pain and anti-inflammatory medication. This would require such a dramatic shift in prescribing Dr. thinking, that I would say it is unrealistic and near impossible.
Regarding the slow release delivery versus capsule. This is a winner, however there is a significant requirement for immediate release pain medication used in combination with a slow release form.
Panadol (Paracetamol) is very cheap, very effective for mild and moderate pain, and has no real adverse effects when taken within the recommended dosage range, and won't be completely replaced by a CBD tablet as far as Drs. are concerned. It is the current "Gold Standard", along with Nurofen.
This is not meant to rain on your parade, just some home truths after decades as a practicing pharmacist.
But, Canntab will have a large potential market, and could make very much bigger sales volumes in Asia, than in Australia. Need to get the majority of prescribers on board first. And get all the licences sorted.

Expand

postscript to my earlier response, some clever little *&%$ has already trademarked Cannadol and Cannadeine

QBL Price at posting: 5.2¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia